Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
55.6M
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
16.6M
-
Shares change
-
-1.27M
-
Total reported value, excl. options
-
$48.2M
-
Value change
-
-$3.74M
-
Number of buys
-
5
-
Number of sells
-
-11
-
Price
-
$2.91
Significant Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q3 2022
30 filings reported holding XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2022.
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.6M shares
of 55.6M outstanding shares and own 29.81% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (2.81M shares), Atlas Venture Life Science Advisors, LLC (2.76M shares), Octagon Capital Advisors LP (2.43M shares), FMR LLC (2.22M shares), RiverVest Venture Management LLC (1.44M shares), Rock Springs Capital Management LP (1.36M shares), VANGUARD GROUP INC (892K shares), AJU IB Investment Co., Ltd. (668K shares), Soleus Capital Management, L.P. (454K shares), and Artal Group S.A. (450K shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.